Search
Dr Sethupathi Muthuramalingam

Dr Sethupathi Muthuramalingam

Medical oncology 05176876

 

  • Bupa Platinum consultant
  • Fee assured
  • Open Referral network
Overview
Bupa Platinum consultant
Fee assured
Open Referral network

About me

I graduated from University of Madras, India and obtained MD in General Medicine from one of the prestigious central institutes (JIPMER) in India. I was awarded a Gold medal by the University for the most outstanding performance in the MD examination.

My general oncology training started in Republic of Ireland and then I spent fours years in the Oxford Medical Oncology training programme leading to the completion of specialist training in oncology (CCST). I took part in various research activities during my training and I was awarded the American Society of Oncology Merit Award for the quality research paper abstract submitted in one of their meetings.

In 2005 I was appointed as a Consultant Medical Oncologist at Portsmouth Hospitals NHS Trust. As an oncologist with a special interest in colorectal, lung cancer and mesothelioma, my expertise is treating cancer patients with chemotherapy, biological therapies, targeted therapies and also immunotherapies.

I also use molecular tests like next generation sequencing (NGS) and genetic tests to guide treatment decisions and reduce the toxicities from treatment. In addition, I take part in many clinical trials and I was the principal investigator of a few of the trials. I have extensive knowledge in managing symptoms associated with cancer and I work very closely with the palliative care and pain team.

Areas of interest

Colorectal (bowel) cancer; Lung cancer, Malignant Mesothelioma
Use of the biological therapies in the treatment of cancer like bevacizumab, cetuximab, Panitumumab.
Use of the targeted therapies in the treatment of cancer like osmertinib, gefitinib, afatinib,criziotinib. Use of the immunotherapies in the treatment of cancer like pembrolizumab, atezilozumab, nivoulumab.
Application of Molecular tests including next generation sequencing (NGS) which help to guide targeted treatments.
Application of Genetic tests like DPD and MSI, which might influence treatment decision making in colorectal cancer patients.

Medical secretaries

About me
My qualifications & training
My private practice
Consultant's practices
Information for healthcare professionals

Information for healthcare professionals (Bupa patients only, last 12 months)

Procedures completed

  • X0004

    Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - (5-50)

    Spire Portsmouth Hospital (5-50)

  • X0002

    Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-14 days - (5-50)

  • X0003

    Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-21 days - (1-5)

    Spire Portsmouth Hospital (1-5)

Report this page Edit details Print page

The information contained on Finder is submitted by consultants, therapists and healthcare services, and is declared by these third parties to be correct and compliant with the standards and codes of conduct specified by their relevant regulatory body. Bupa cannot guarantee the accuracy of all of the information provided.

You can find out more about the information on Finder and our website terms of use.